These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69 related articles for article (PubMed ID: 15214806)
1. Computer-aided molecular design of novel glucosidase inhibitors for AIDS treatment. Silva CH; Taft CA J Biomol Struct Dyn; 2004 Aug; 22(1):59-63. PubMed ID: 15214806 [TBL] [Abstract][Full Text] [Related]
2. Homology modeling and molecular interaction field studies of alpha-glucosidases as a guide to structure-based design of novel proposed anti-HIV inhibitors. Tomich CH; da Silva P; Carvalho I; Taft CA J Comput Aided Mol Des; 2005 Feb; 19(2):83-92. PubMed ID: 16075303 [TBL] [Abstract][Full Text] [Related]
3. Crystal structure of Thermotoga maritima 4-alpha-glucanotransferase and its acarbose complex: implications for substrate specificity and catalysis. Roujeinikova A; Raasch C; Sedelnikova S; Liebl W; Rice DW J Mol Biol; 2002 Aug; 321(1):149-62. PubMed ID: 12139940 [TBL] [Abstract][Full Text] [Related]
4. Docking and SAR studies of salacinol derivatives as alpha-glucosidase inhibitors. Nakamura S; Takahira K; Tanabe G; Morikawa T; Sakano M; Ninomiya K; Yoshikawa M; Muraoka O; Nakanishi I Bioorg Med Chem Lett; 2010 Aug; 20(15):4420-3. PubMed ID: 20598536 [TBL] [Abstract][Full Text] [Related]
5. Binding mode analyses and pharmacophore model development for sulfonamide chalcone derivatives, a new class of alpha-glucosidase inhibitors. Bharatham K; Bharatham N; Park KH; Lee KW J Mol Graph Model; 2008 Jun; 26(8):1202-12. PubMed ID: 18096420 [TBL] [Abstract][Full Text] [Related]
6. Computational anti-AIDS drug design based on the analysis of the specific interactions between immunophilins and the HIV-1 gp120 V3 loop. Application to the FK506-binding protein. Andrianov AM J Biomol Struct Dyn; 2008 Aug; 26(1):49-56. PubMed ID: 18533725 [TBL] [Abstract][Full Text] [Related]
7. Homonojirimycin isomers and N-alkylated homonojirimycins: structural and conformational basis of inhibition of glycosidases. Asano N; Nishida M; Kato A; Kizu H; Matsui K; Shimada Y; Itoh T; Baba M; Watson AA; Nash RJ; Lilley PM; Watkin DJ; Fleet GW J Med Chem; 1998 Jul; 41(14):2565-71. PubMed ID: 9651160 [TBL] [Abstract][Full Text] [Related]
8. Discovery of novel alpha-glucosidase inhibitors based on the virtual screening with the homology-modeled protein structure. Park H; Hwang KY; Oh KH; Kim YH; Lee JY; Kim K Bioorg Med Chem; 2008 Jan; 16(1):284-92. PubMed ID: 17920282 [TBL] [Abstract][Full Text] [Related]
9. Computational model of the HIV-1 subtype A V3 loop: study on the conformational mobility for structure-based anti-AIDS drug design. Andrianov AM; Anishchenko IV J Biomol Struct Dyn; 2009 Oct; 27(2):179-93. PubMed ID: 19583444 [TBL] [Abstract][Full Text] [Related]
10. How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? Mechanistic insights from computational modeling and the implication for rational design of anti-HIV-1 entry inhibitors. Hamza A; Zhan CG J Phys Chem B; 2006 Feb; 110(6):2910-7. PubMed ID: 16471901 [TBL] [Abstract][Full Text] [Related]
11. A pharmacophore docking algorithm and its application to the cross-docking of 18 HIV-NNRTI's in their binding pockets. Daeyaert F; de Jonge M; Heeres J; Koymans L; Lewi P; Vinkers MH; Janssen PA Proteins; 2004 Feb; 54(3):526-33. PubMed ID: 14748000 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of HIV-1 integrase by small molecules: the potential for a new class of AIDS chemotherapeutics. Young SD Curr Opin Drug Discov Devel; 2001 Jul; 4(4):402-10. PubMed ID: 11727305 [TBL] [Abstract][Full Text] [Related]
13. Discovery and biological evaluation of novel alpha-glucosidase inhibitors with in vivo antidiabetic effect. Park H; Hwang KY; Kim YH; Oh KH; Lee JY; Kim K Bioorg Med Chem Lett; 2008 Jul; 18(13):3711-5. PubMed ID: 18524587 [TBL] [Abstract][Full Text] [Related]
14. Enzymatic synthesis of a selective inhibitor for alpha-glucosidases: alpha-acarviosinyl-(1-->9)-3-alpha-D-glucopyranosylpropen. Lee YS; Lee MH; Lee HS; Lee SJ; Kim YW; Zhang R; Withers SG; Kim KS; Lee SJ; Park KH J Agric Food Chem; 2008 Jul; 56(13):5324-30. PubMed ID: 18553919 [TBL] [Abstract][Full Text] [Related]
15. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling. Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092 [TBL] [Abstract][Full Text] [Related]
16. Virtual ligand screening of α-glucosidase: Identification of a novel potent noncarbohydrate mimetic inhibitor. Hakamata W; Ishikawa R; Ushijima Y; Tsukagoshi T; Tamura S; Hirano T; Nishio T Bioorg Med Chem Lett; 2012 Jan; 22(1):62-4. PubMed ID: 22154663 [TBL] [Abstract][Full Text] [Related]
17. Novel anti-HIV cyclotriazadisulfonamide derivatives as modeled by ligand- and receptor-based approaches. Pinheiro JR; Bitencourt M; da Cunha EF; Ramalho TC; Freitas MP Bioorg Med Chem; 2008 Feb; 16(4):1683-90. PubMed ID: 18053727 [TBL] [Abstract][Full Text] [Related]
18. Potential of polymeric nanoparticles in AIDS treatment and prevention. Khalil NM; Carraro E; Cótica LF; Mainardes RM Expert Opin Drug Deliv; 2011 Jan; 8(1):95-112. PubMed ID: 21143001 [TBL] [Abstract][Full Text] [Related]
19. Glucosidase inhibitors as antiviral agents for hepatitis B and C. Durantel D; Alotte C; Zoulim F Curr Opin Investig Drugs; 2007 Feb; 8(2):125-9. PubMed ID: 17328228 [TBL] [Abstract][Full Text] [Related]
20. Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant. Ragno R; Mai A; Sbardella G; Artico M; Massa S; Musiu C; Mura M; Marturana F; Cadeddu A; La Colla P J Med Chem; 2004 Feb; 47(4):928-34. PubMed ID: 14761194 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]